within Pharmacolibrary.Drugs.ATC.N;

model N06AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.6666666666666666,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Zimeldine is a selective serotonin reuptake inhibitor (SSRI) that was originally developed and used as an antidepressant in the early 1980s. However, it was withdrawn from the market shortly after its introduction due to reports of serious adverse effects such as Guillain–Barré syndrome. Zimeldine is not approved for use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects, as no precise data are available in published literature.</p><h4>References</h4><ol><li><p>Gottfries, CG, et al., &amp; Alling, C (1986). Pharmacokinetics of zimeldine in male alcoholics. <i>Acta pharmacologica et toxicologica</i> 59(2) 94–102. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0773.1986.tb00140.x&quot;>10.1111/j.1600-0773.1986.tb00140.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2946168/&quot;>https://pubmed.ncbi.nlm.nih.gov/2946168</a></p></li><li><p>Love, BL, et al., &amp; Chaturvedi, S (1981). Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. <i>European journal of clinical pharmacology</i> 20(2) 135–139. DOI:<a href=&quot;https://doi.org/10.1007/BF00607150&quot;>10.1007/BF00607150</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6455297/&quot;>https://pubmed.ncbi.nlm.nih.gov/6455297</a></p></li><li><p>Caillé, G, et al., &amp; de Montigny, C (1983). Pharmacokinetic study of zimelidine using a new GLC method. <i>Clinical pharmacokinetics</i> 8(6) 530–540. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198308060-00004&quot;>10.2165/00003088-198308060-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6228368/&quot;>https://pubmed.ncbi.nlm.nih.gov/6228368</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AB02;
